Travere Therapeutics, Inc. TVTX 深 沪
等待开盘 02-11 09:30:00 美东时间
30.32
+0.250
+0.83%
华盛通- 最 高30.65
- 今 开30.12
- 成交量 65.97万股
- 最 低 29.63
- 昨 收 30.07
- 总市值 27.13亿
- 52周最高 42.13
- 市盈率 静 --
- 换手率 0.74%
- 52周最低 12.91
- 委 比 -67.72%
- 总股本 8947.23万
- 历史最高 42.13
- 量 比 0.47
- 振 幅 3.39%
- 历史最低 0.90
- 每 手 1
- 风险率 7.53%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 遭多家大行下调目标价！亚马逊、Affirm、Roblox、汤森路透、Doximity、OneMain、Atlassian、Peloton等等
今日重点评级关注：HC Wainwright & Co.：维持NovaBridge Biosciences"买入"评级，目标价从7美元升至9美元；Truist Securities：维持Reddit"买入"评级，目标价从270美元升至275美元
02-09 14:37
Piper Sandler Maintains Neutral on Travere Therapeutics, Raises Price Target to $38
Piper Sandler analyst Allison Bratzel maintains Travere Therapeutics (NASDAQ:TVTX) with a Neutral and raises the price target from $35 to $38.
02-06 23:55
Top 3 Health Care Stocks That Could Blast Off This Month
The most oversold stocks in the health care sector presents an opportunity to b...
01-21 19:41
Travere Therapeutics Expects Total U.S. Net Product Sales For Q4 2025 To Be ~$127M; Expects $410M U.S. Net Product Sales For 2025; Co. To Restart Phase 3 HARMONY Study In Q1 2026; PDUFA Target Date For Filspari Approval Is January 13, 2026
Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that, based on preliminary and unaudited financial data, the Company expects total U.S. net product sales for the fourth quarter of 2025 to be approximately $127
01-13 06:05
美股牛股 | 奥麦罗制药涨超75%，YARTEMLEA药物获得FDA批准；德纳维制药涨超38%
奥麦罗制药涨超75%，YARTEMLEA药物获得FDA批准；德纳维制药涨超38%，获法国制药巨头22亿美元收购；Sidus Space涨超33%，获美国导弹防御局合同>>
2025-12-26 18:41
Dynavax Technologies, Omeros, Agios Pharmaceuticals, Nike And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on ...
2025-12-25 00:06
美股大行评级 | 美银证券下调哔哩哔哩目标价至31美元；高盛下调诺和诺德目标价至54美元
今日重点评级关注：Benchmark：维持Grupo Televisa"买入"评级，目标价从9美元升至10美元；Truist Securities：维持迪尔股份"买入"评级，目标价从609美元升至612美元
2025-12-01 14:33
HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $47 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Travere Therapeutics (NASDAQ:TVTX) with a Buy and maintains $47 price target.
2025-11-28 19:57
美股大行评级 | 最高255美元！9家大行集体上调Palantir目标价；Axsome、Exact、Fabrinet、ZoomInfo、爱德士、MongoDB、安森美半导体等也获多家大行上调目标价
今日重点评级关注：瑞银：维持Syndax Pharmaceuticals"买入"评级，目标价从35美元升至38美元；HC Wainwright & Co.：维持Benitec Biopharma"买入"评级，目标价从28美元升至35美元
2025-11-05 10:35
